Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelnorm uptake

Executive Summary

More than 70% of "top-tier" gastrointestinal specialists are prescribing the irritable bowel syndrome agent Zelnorm, Novartis Pharmaceutical CEO Thomas Ebeling tells investors April 15. "Tier one" physicians have on average 16-18 patients on tegaserod, he says. By comparison, second and third tier specialists have six to eight patients on the IBS agent, with roughly 45% and 35% of tier two and three physicians prescribing, respectively. Novartis previously described uptake for the specialist community as a whole, with 25% prescribing Zelnorm (1"The Pink Sheet" Oct. 21, 2002, p. 24)...

You may also be interested in...



Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months

The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City

France Rejects Advice To Delay Second Dose Of Pfizer Vaccine

The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine. 

Biosimilars Boost Offsets Generics Slide For Sandoz

Despite the turbulence of 2020 and the pressures of the coronavirus pandemic, Sandoz has reported steady sales for the year, as biopharmaceuticals sales up by a fifth offset a slide in turnover from retail generics.

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel